|
Synonyms: BPS 804 | BPS804 | UX-143 | UX143
Compound class:
Antibody
Comment: Setrusumab (BPS-804) is a fully human investigational monoclonal antibody targeting sclerostin (SOST; which is a negative regulator of bone formation), that is intended to improve bone density.
Development of anti-sclerostin antibodies by Novartis is claimed in patent WO2009047356 [3], although we cannot definitively conclude that BPS-804 is claimed within that patent application. The potential of sclerostin as a therapeutic target in bone diseases was reviewed by Lewiecki (2014) [4]. |
| No information available. |
Summary of Clinical Use ![]() |
| UX-143/BPS-804 completed Phase 2 and 3 clinical trial in patients with osteogenesis imperfecta, a.k.a. brittle bone syndrome (NCT01417091) [1]. Development for hypophosphatasia and postmenopausal osteoporosis was discontinued. The agent has both U.S. and EU orphan drug designation for osteogenesis imperfecta. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
| BPS-804 binds to sclerostin, an osteocyte protein which normally inhibits Wnt signalling and decreases bone formation by osteoblasts [2,6] as part of the regulatory system controlling bone mass equilibrium. Neutralisation of sclerostin activity leads to improved bone formation in animal models, as reported for another anti-sclerostin antibody, romosozumab [5,7]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01417091 | Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta | Phase 2 Interventional | Novartis | ||
| NCT03118570 | A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | Phase 2 Interventional | Ultragenyx Pharmaceutical Inc | ||
| NCT05125809 | Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta | Phase 2/Phase 3 Interventional | Ultragenyx Pharmaceutical Inc | The ORBIT study | |
| NCT05768854 | Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta | Phase 3 Interventional | Ultragenyx Pharmaceutical Inc | The COSMIC study | |